{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:30Z","timestamp":1793323350660,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently available antiretroviral 2-drug regimen (2DR) fixed dose combinations may not be suitable for specific situations including the presence of resistance associated mutations (RAM) or drug\u2009\u2212\u2009drug interactions\u00a0(DDI). The data on the use of the non-nucleoside reverse transcriptase inhibitor doravirine (DOR) and the integrase inhibitor dolutegravir (DTG) as an alternative 2DR remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>People living with HIV with DOR\u2009+\u2009DTG as a 2DR are being followed in a prospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis describes 85 participants with a median age of 57\u00a0years. Median CD4-nadir was 173\/\u00b5l and a majority (66%) had a history of HIV-associated or AIDS-defining conditions. Antiretroviral history was mostly extensive, and documentation of RAM was frequent. The main reasons for choosing DOR\u2009+\u2009DTG were DDI (29%), tolerability (25%), and cardiovascular risk reduction (21%). Plasma viral load at switch was\u2009&lt;\u200950 copies\/ml in all but 3 instances, median CD4 count was 600\/\u00b5l. DOR\u2009+\u2009DTG was later changed to another regimen in 10 participants after a median of 265\u00a0days, the other 75 participants have remained on DOR\u2009+\u2009DTG for a median of 947\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DOR\u2009+\u2009DTG as a 2DR proved to be a durable treatment option even in extensively pretreated individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-023-02075-y","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T05:02:33Z","timestamp":1690866153000},"page":"1823-1829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir"],"prefix":"10.1007","volume":"51","author":[{"given":"Stefanie","family":"Sammet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Touzeau-R\u00f6mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Schenk-Westkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Gersbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kastenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Boesecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Scholten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Roider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Seybold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"2075_CR1","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10:e295\u2013307. https:\/\/doi.org\/10.1016\/S2352-3018(23)00028-0.","journal-title":"Lancet HIV"},{"key":"2075_CR2","unstructured":"European AIDS Clinical Society. Guidelines Version 11.1. 2022; available at https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09-10.pdf. Accessed on June 16 2022"},{"key":"2075_CR3","unstructured":"Deutsche AIDS-Gesellschaft. Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion, Version 9. 2020; available at https:\/\/daignet.de\/site-content\/hiv-leitlinien\/leitlinien-1\/deutsch-oesterreichische-leitlinien-zur-antiretroviralen-therapie-der-hiv-infektion . Accessed on 16 June 2023"},{"key":"2075_CR4","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. 2023; available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed 20 June 2023"},{"key":"2075_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/QAI.0000000000003019","volume":"91","author":"JM Llibre","year":"2022","unstructured":"Llibre JM, Lopez Cortes LF, Aylott A, et al. Brief report: evaluation of inflammation and atherogenesis biomarkers through 148 weeks postswitch to dolutegravir and rilpivirine in SWORD-1\/SWORD-2. J Acquir Immune Defic Syndr. 2022;91:73\u20138. https:\/\/doi.org\/10.1097\/QAI.0000000000003019.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2075_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104474","volume":"9","author":"D Schmidt","year":"2014","unstructured":"Schmidt D, Kollan C, Fatkenheuer G, et al. Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany. PLoS One. 2014;9: e104474. https:\/\/doi.org\/10.1371\/journal.pone.0104474.","journal-title":"PLoS One"},{"key":"2075_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","volume":"88","author":"A Ciccullo","year":"2021","unstructured":"Ciccullo A, Borghi V, Giacomelli A, et al. Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. J Acquir Immune Defic Syndr. 2021;88:234\u20137. https:\/\/doi.org\/10.1097\/QAI.0000000000002787.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2075_CR8","first-page":"87","volume":"15","author":"H Crauwels","year":"2013","unstructured":"Crauwels H, van Heeswijk RP, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15:87\u2013101.","journal-title":"AIDS Rev"},{"key":"2075_CR9","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","volume":"7","author":"JM Molina","year":"2020","unstructured":"Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020;7:e16\u201326. https:\/\/doi.org\/10.1016\/S2352-3018(19)30336-4.","journal-title":"Lancet HIV"},{"key":"2075_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","volume":"81","author":"M Johnson","year":"2019","unstructured":"Johnson M, Kumar P, Molina JM, et al. Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019;81:463\u201372. https:\/\/doi.org\/10.1097\/QAI.0000000000002056.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2075_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","volume":"68","author":"C Orkin","year":"2019","unstructured":"Orkin C, Squires KE, Molina JM, et al. Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68:535\u201344. https:\/\/doi.org\/10.1093\/cid\/ciy540.","journal-title":"Clin Infect Dis"},{"key":"2075_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijantimicag.2019.02.007","volume":"53","author":"G Sterrantino","year":"2019","unstructured":"Sterrantino G, Borghi V, Callegaro AP, et al. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019;53:515\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.02.007.","journal-title":"Int J Antimicrob Agents"},{"key":"2075_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40261-017-0512-5","volume":"37","author":"MO Behm","year":"2017","unstructured":"Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig. 2017;37:571\u20139. https:\/\/doi.org\/10.1007\/s40261-017-0512-5.","journal-title":"Clin Drug Investig"},{"key":"2075_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40262-016-0458-4","volume":"56","author":"MS Anderson","year":"2017","unstructured":"Anderson MS, Khalilieh S, Yee KL, et al. A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir. Clin Pharmacokinet. 2017;56:661\u20139. https:\/\/doi.org\/10.1007\/s40262-016-0458-4.","journal-title":"Clin Pharmacokinet"},{"key":"2075_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/09564624221116533","author":"R Denyer","year":"2022","unstructured":"Denyer R, Zemskova J, Benator DA. HIV treatment with dolutegravir and doravirine: rationale for selection and clinical outcomes in a highly treatment experienced population. Int J STD AIDS. 2022. https:\/\/doi.org\/10.1177\/09564624221116533.","journal-title":"Int J STD AIDS"},{"key":"2075_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028488","volume":"100","author":"M Mazzitelli","year":"2021","unstructured":"Mazzitelli M, Sasset L, Leoni D, Putaggio C, Cattelan AM. Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis. Medicine (Baltimore). 2021;100: e28488. https:\/\/doi.org\/10.1097\/MD.0000000000028488.","journal-title":"Medicine (Baltimore)"},{"key":"2075_CR17","unstructured":"mib medizinisches Infektiologiezentrum AG. HIV-GRADE HIV-1 tool, Mutations List Analysis. 2023; available at https:\/\/www.hiv-grade.de\/grade_new\/ . Accessed on 16 June 2023."},{"key":"2075_CR18","unstructured":"an der Heiden M, Marcus U, Kollan C, et al. Sch\u00e4tzung der Anzahl von HIV-Neuinfektionen im Jahr 2021 und der Gesamtzahl von Menschen, die Ende 2021 mit HIV in Deutschland leben. Epid Bull 2022;47:3\u201318. 0.25646\/10814"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02075-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T06:06:49Z","timestamp":1700633209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02075-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2075"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02075-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2869311\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.S.: Advisory board honorarium from MSD. Travel\/conference support from Gilead Sciences.\nE.W.: Honoraria for lectures, advisory boards or registration\/travel expenses from AbbVie, Biogen, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare. Involved in (research) projects supported by AbbVie, Gilead Sciences, Janssen-Cilag, MSD, ViiV Healthcare.\nC.B.: Honoraria for lectures and\/or consultancies from AbbVie, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID.\nJ.Roc.: Honoraria for lectures and\/or consultancies from AbbVie, Boehringer, Galapagos, Gilead Sciences, Janssen, MSD, ViiV. Funding from DFG, Dt. Leberstiftung, DZIF, Hector Stiftung, NEAT ID.\nS.Scho.: Speakers\u2019 honoraria from ViiV, Gilead Sciences, Janssen, Cepheid. Honoraria for consultancies from Gilead Sciences, ViiV. Travel\/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, INSTO, Heidelberg Therapeutics.\nS.Schn.: Speakers\u2019 honoraria from ViiV, MSD, INSTO. Honoraria for consultancies from ViiV. Travel\/conference support from Gilead Sciences, Janssen, ViiV. Funding from GSK, ViiV, Gilead Sciences, Heidelberg Therapeutics.\nJ.Roi.: Speakers\u2019 honoraria from Gilead Sciences. Funding from DZIF, Else Kr\u00f6ner-Fresenius-Stiftung\nU.S.: Speakers\u2019 honoraria from Gilead Sciences, ViiV, Janssen Cilag. Honoraria for consultancies from Gilead Sciences and ViiV. Travel\/conference support from Gilead, ViiV. Poster award from Hector Stiftung.\nAll other authors: no perceived potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The study protocol has been approved by the Ethics Committee at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen (project number 21-0044) and all ethics committees responsible for the specific study sites. The study has been submitted to the German Registry for Clinical Studies (DRKS) with the ID 00030471. Written informed consent was obtained from all participants before inclusion into the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}